Raymond Townsend - 27 Aug 2021 Form 4 Insider Report for Kindred Biosciences, Inc.

Role
Director
Signature
/s/ Raymond Townsend
Issuer symbol
N/A
Transactions as of
27 Aug 2021
Net transactions value
-$906,133
Form type
4
Filing time
30 Aug 2021, 15:45:59 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KIN Common Stock Disposed to Issuer $230,584 -24,928 -100% $9.25 0 27 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KIN Stock Option (right to buy) Disposed to Issuer $45,000 -20,000 -100% $2.25* 0 27 Aug 2021 Common Stock 20,000 $7.00 Direct F2
transaction KIN Stock Option (right to buy) Disposed to Issuer $0 -34,000 -100% $0.000000* 0 27 Aug 2021 Common Stock 34,000 $15.41 Direct F3
transaction KIN Stock Option (right to buy) Disposed to Issuer $100,760 -44,000 -100% $2.29* 0 27 Aug 2021 Common Stock 44,000 $6.96 Direct F4
transaction KIN Stock Option (right to buy) Disposed to Issuer $109,574 -18,892 -100% $5.80 0 27 Aug 2021 Common Stock 18,892 $3.45 Direct F5
transaction KIN Stock Option (right to buy) Disposed to Issuer $142,215 -49,900 -100% $2.85 0 27 Aug 2021 Common Stock 49,900 $6.40 Direct F6
transaction KIN Stock Option (right to buy) Disposed to Issuer $37,500 -75,000 -100% $0.5000* 0 27 Aug 2021 Common Stock 75,000 $8.75 Direct F7
transaction KIN Stock Option (right to buy) Disposed to Issuer $0 -50,000 -100% $0.000000* 0 27 Aug 2021 Common Stock 50,000 $9.91 Direct F8
transaction KIN Stock Option (right to buy) Disposed to Issuer $0 -50,000 -100% $0.000000* 0 27 Aug 2021 Common Stock 50,000 $9.84 Direct F9
transaction KIN Stock Option (right to buy) Disposed to Issuer $240,500 -50,000 -100% $4.81 0 27 Aug 2021 Common Stock 50,000 $4.44 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Raymond Townsend is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents 24,928 shares of common stock that were disposed of at the effective time of the merger (the "Merger") contemplated by the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement") in exchange for a cash payment of $9.25 per share.
F2 This option, which vested 25% of the total number of shares underlying the option ("Option Shares") on the annual anniversary of December 11, 2013, with the remaining Option Shares vested in equal monthly installments over the following three years, subject to continued service as director on each such vesting date, was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $45,000.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
F3 This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
F4 This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $100,760.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
F5 This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $109,573.60, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
F6 This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $142,215.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
F7 This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $37,500.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.
F8 This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
F9 This option provided for vesting in four equal quarterly installments from the option grant date. This option was cancelled pursuant to the Merger Agreement in exchange for no consideration.
F10 This option provided for vesting in four equal quarterly installments from the option grant date. Pursuant to the Merger Agreement, the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $240,500.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.